What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3

State Street Health Care Select Sector SPDR ETF (XLV) bought $330.3M in stocks on Nov. 3, increasing all 60 holdings. Top purchases included Eli Lilly (LLY) at $56.0M, Johnson & Johnson (JNJ) at $31.8M, and AbbVie (ABBV) at $25.1M. XLV has $49.13B in assets and a 0.08% expense ratio.

Original reporting
Published Nov 5, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 11:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Nov. 3 — source image
Decision brief

The 30-second read

$LLYBullishLow
01

Why it matters

ETF inflows can provide short‑term support to the listed health‑care stocks, but the effect is modest without accompanying corporate news.

02

Market read

Fund’s buying adds incremental demand to top health‑care stocks; limited trading relevance.

03

What to watch

No new product or earnings news; the buying is purely allocation‑driven.

Relevance 4/10Novelty 2/10Timing: today

Background

The article reports daily net buying activity of the XLV ETF, highlighting its largest holdings added on Nov 3.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

State Street Health Care SPDR ETF (XLV) bought $56.0 million of Eli Lilly shares, adding 39,730 shares.

Expected impact

likely modest upside as the ETF increases buying pressure

Evidence & confidence

Large institutional purchase can lift price in the short term.

$JNJBullishHigh confidence
Context

XLV purchased $31.8 million of Johnson & Johnson shares, adding 119,488 shares.

Expected impact

likely slight upward pressure from the fund’s buying

Evidence & confidence

Even a modest fund purchase can support the stock.

$ABBVBullishHigh confidence
Context

XLV bought $25.1 million of AbbVie shares, adding 87,592 shares.

Expected impact

potential modest price lift from the new buying

Evidence & confidence

Institutional buying tends to be viewed positively.

$UNHBullishHigh confidence
Context

XLV added $18.0 million of UnitedHealth Group shares, buying 44,480 shares.

Expected impact

likely modest upside as the fund increases exposure

Evidence & confidence

Large‑cap stocks often react positively to fund inflows.

$MRKBullishHigh confidence
Context

XLV purchased $17.7 million of Merck shares, adding 122,156 shares.

Expected impact

likely slight upward pressure from the fund’s purchase

Evidence & confidence

Even incremental buying by a major ETF can be supportive.

Market effects

Broad health‑care sector sees net buying pressure from a large ETF, supporting sector sentiment.

U.S. equity market receives modest inflow into health‑care stocks.

Limited; impact confined to U.S. health‑care equities.

Counterpoint

Fund buying may already be priced in; further upside limited.

Key entities

  • State Street Health Care Select Sector SPDR ETF

    Large health‑care sector ETF with $49.13 bn AUM.

Related articles

$JNJHighAI 9/10

J&J posts trial win for psoriatic arthritis pill (JNJ:NYSE)

Johnson & Johnson (JNJ) reported that Icotyde, a therapy co-marketed with Protagonist Therapeutics (PTGX), showed success in a late-stage trial for psoriatic arthritis, according to the company. The drug is already FDA-approved for plaque psoriasis. Up to 30% of plaque psoriasis patients also develop psoriatic arthritis, per studies.

$JNJHighAI 8/10

J&J's once-daily pill eases psoriatic arthritis symptoms in late-stage trial

Johnson & Johnson reported that its once-daily pill, Icotyde, showed significant improvement in psoriatic arthritis symptoms in a late-stage trial. 58% of patients taking Icotyde saw a 20% improvement in joint counts and disease activity, compared to 41% on placebo. The drug is already FDA-approved for psoriasis and could expand into psoriatic arthritis, with peak sales expected to exceed $5 billion.

$JNJMed

In J&J's psoriatic arthritis study, a pill cleared or nearly cleared skin in 57% of patients with skin involvement.

Johnson & Johnson's Phase 3 study of ICOTYDE for psoriatic arthritis showed 58% of patients achieved an ACR20 response at Week 16, with 57% clearing or nearly clearing skin lesions. The once-daily oral peptide demonstrated joint and skin improvements, according to data presented at the American College of Rheumatology Convergence. ICOTYDE is not yet approved for psoriatic arthritis treatment.

$JNJMed

Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

Johnson & Johnson (JNJ) presented new Phase 2 data on nipocalimab for Sjögren's disease, showing mouth dryness as the most critical symptom for patients. The study found a 50% increase in saliva production in more patients treated with nipocalimab compared to placebo. Two Phase 3 studies are ongoing, focusing on patient-valued outcomes. Nipocalimab has received Breakthrough Therapy and Fast Track Designations from the FDA for this indication.